Skip to main content
×
×
Home

Can a digital medicine system improve adherence to antipsychotic treatment?

  • D. Papola (a1), C. Gastaldon (a1) and G. Ostuzzi (a1)
Abstract

A substantial proportion of people with mental health conditions do not adhere to prescribed pharmacological treatments. Poor adherence is probably one of the most critical elements contributing to relapse in people with schizophrenia and other severe mental disorders. In order to tackle this global issue, in November 2017 the Food and Drug Administration approved a tablet formulation of the atypical antipsychotic aripiprazole embedded with a novel digital adherence-assessment device. In this commentary, we critically appraised the potential beneficial and harmful consequences of this new digital formulation of aripiprazole, and we highlighted expected implications for clinical practice.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Can a digital medicine system improve adherence to antipsychotic treatment?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Can a digital medicine system improve adherence to antipsychotic treatment?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Can a digital medicine system improve adherence to antipsychotic treatment?
      Available formats
      ×
Copyright
Corresponding author
*Address for correspondence: Dr Davide Papola, Section of Psychiatry, University of Verona, Ospedale Policlinico GB Rossi, Piazzale L.A. Scuro, 10 – 37134 Verona, Italy. (E-mail: candido09@hotmail.it)
Footnotes
Hide All

This Section of Epidemiology and Psychiatric Sciences appears in each issue of the Journal to stress the role of the epidemiological approach to promote advances in the field of clinical psychopharmacology, with a particular attention to controversial findings. The ultimate aims are to help develop a more critical attitude towards the results of research studies published in the international literature, to promote original research projects with higher methodological standards, and to implement the most relevant results of research in every-day clinical practice. These contributions are written in house by the journal's editorial team or commissioned by the Section Editor (no more than 1000 words, short unstructured abstract, 4 key-words, one Table or Figure and up to ten references).

Corrado Barbui, Section Editor

Footnotes
References
Hide All
Belluck, P (2017). First Digital Pill Approved to Worries About Biomedical ‘Big Brother’. The New York Times. Retrieved 30 November 2017 from https://www.nytimes.com/2017/11/13/health/digital-pill-fda.html.
Carson, WH (2015). Abilify MyCite - U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka and Proteus Digital Health. Retrieved 5 December 2017 from https://www.drugs.com/nda/abilify_digital_150910.html.
Chen, EY, Hui, CL, Dunn, EL, Miao, MY, Yeung, WS, Wong, CK, Chan, WF, Tang, WN (2005). A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophrenia Research 77, 99104.
Das, AK, Malik, A, Haddad, PM (2014). A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Therapeutic Advances in Psychopharmacology 4, 179185.
Frias, J, Virdi, N, Raja, P, Kim, Y, Savage, G, Osterberg, L (2017). Effectiveness of digital medicines to improve clinical outcomes in patients with uncontrolled hypertension and type 2 diabetes: prospective, open-label, cluster-randomized pilot clinical trial. Journal of Medical Internet Research 19, e246.
Kane, JM, Perlis, RH, DiCarlo, LA, Au-Yeung, K, Duong, J, Petrides, G (2013). First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. Journal of Clinical Psychiatry 74, e533e540.
Kirschner, M, Theodoridou, A, Fusar-Poli, P, Kaiser, S, Jager, M (2013). Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Therapeutic Advances in Psychopharmacology 3, 8999.
Kopelowicz, A, Baker, RA, Zhao, C, Brewer, C, Lawson, E, Peters-Strickland, T (2017). A multicenter, open-label, pilot study evaluating the functionality of an integrated call center for a digital medicine system to optimize monitoring of adherence to oral aripiprazole in adult patients with serious mental illness. Neuropsychiatric Disease and Treatment 13, 26412651.
Marder, SR (2003). Overview of partial compliance. Journal of Clinical Psychiatry 64(Suppl. 16), 39.
Nieuwlaat, R, Wilczynski, N, Navarro, T, Hobson, N, Jeffery, R, Keepanasseril, A, Agoritsas, T, Mistry, N, Iorio, A, Jack, S, Sivaramalingam, B, Iserman, E, Mustafa, RA, Jedraszewski, D, Cotoi, C, Haynes, RB (2014). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 11, CD000011. doi: 10.1002/14651858.CD000011.pub4.
Otsuka Pharmaceutical Co. (2017). Abilify MyCite's prescribing information (labeling) notes. Retrieved 2 December 2017 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207202lbl.pdf
Peters-Strickland, T, Pestreich, L, Hatch, A, Rohatagi, S, Baker, RA, Docherty, JP, Markovtsova, L, Raja, P, Weiden, PJ, Walling, DP (2016). Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatric Disease and Treatment 12, 25872594.
WHO (2003). Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization. Retrieved 2 December 2017 from http://www.who.int/chp/knowledge/publications/adherence_report/en/.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology and Psychiatric Sciences
  • ISSN: 2045-7960
  • EISSN: 2045-7979
  • URL: /core/journals/epidemiology-and-psychiatric-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed